About Verici Dx
Verici Dx is a company based in New York (United States) founded in 2020.. Verici Dx offers products and services including Tutivia™, Clarava™, and Protega™. Verici Dx operates in a competitive market with competitors including Oxford Immunotec, Immucor, Olaris, Transplant Genomics and Nephrosant, among others.
- Headquarter New York, United States
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Verici Dx Plc
-
Annual Revenue
$3.27 M (USD)220.65as on Dec 31, 2024
-
Net Profit
$-5.76 M (USD)34.58as on Dec 31, 2024
-
EBITDA
$-5.29 M (USD)32.4as on Dec 31, 2024
-
Latest Funding Round
$353.27 K (USD), Post-IPO
Feb 14, 2024
-
Investors
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Verici Dx
Verici Dx is a publicly listed company on the LSE with ticker symbol VRCI in UK, operating in the Health services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Verici Dx
Verici Dx offers a comprehensive portfolio of products and services, including Tutivia™, Clarava™, and Protega™. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
RNA signature test for kidney transplant risk scoring.
Test for assessing transplant-related immune responses.
AI-driven tool for monitoring graft failure risks.
Unlock access to complete
Leadership Team
2 people
Software Development Team
2 people
Independent Team
1 people
Operations Team
1 people
Unlock access to complete
Funding Insights of Verici Dx
- Total Funding Total Funding
- Total Rounds 3
- Last Round Post-IPO — $353,273
-
First Round
First Round
(06 Nov 2020)
- Investors Count Investors Count
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb, 2024 | Amount | Post-IPO - Verici Dx | Valuation |
investors |
|
| Jan, 2024 | Amount | Post-IPO - Verici Dx | Valuation |
investors |
|
| Nov, 2020 | Amount | Post-IPO - Verici Dx | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investments & Acquisitions by Verici Dx
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Verici Dx
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Verici Dx Comparisons
Competitors of Verici Dx
Verici Dx operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Oxford Immunotec, Immucor, Olaris, Transplant Genomics and Nephrosant, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Immune markers are utilized by Oxford Immunotec for disease diagnostics.
|
|
| domain | founded_year | HQ Location |
Transfusion and transplantation diagnostic products are provided by Immucor.
|
|
| domain | founded_year | HQ Location |
In-vitro diagnostics are developed for oncology, transplants, and neurodegeneration.
|
|
| domain | founded_year | HQ Location |
Molecular diagnostic tests for early graft injury detection are developed.
|
|
| domain | founded_year | HQ Location |
Developer of diagnostic solutions for kidney disorders
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Verici Dx
Frequently Asked Questions about Verici Dx
When was Verici Dx founded?
Verici Dx was founded in 2020.
Where is Verici Dx located?
Verici Dx is headquartered in New York, United States. It is registered at New York, New York, United States.
What is the annual revenue of Verici Dx?
Annual revenue of Verici Dx is $3.27M as on Dec 31, 2024.
What does Verici Dx do?
Verici Dx was founded in 2020 and is based in New York, United States. Diagnostic solutions for organ transplants are provided within the biotechnology sector. Kidney transplant assays have been developed by integrating sequencing science, transcriptomic analysis, clinical records, and pathological data. Risks associated with kidney injury diagnosis and graft loss are addressed through these tools, supporting transplant outcomes in clinical settings.
Who are the top competitors of Verici Dx?
Verici Dx's top competitors include Olaris, Oxford Immunotec and Nephrosant.
What products or services does Verici Dx offer?
Verici Dx offers Tutivia™, Clarava™, and Protega™.
Is Verici Dx publicly traded?
Yes, Verici Dx is publicly traded on LSE under the ticker symbol VRCI.
What is Verici Dx's ticker symbol?
The ticker symbol of Verici Dx is VRCI on LSE.